Teresa Lambe
#82,215
Most Influential Person Now
Irish vaccinologist
Teresa Lambe's AcademicInfluence.com Rankings
Teresa Lambebiology Degrees
Biology
#7642
World Rank
#10593
Historical Rank
Immunology
#986
World Rank
#1010
Historical Rank
Download Badge
Biology
Teresa Lambe's Degrees
- Bachelors Biomedical Science National University of Ireland
- PhD Immunology Trinity College Dublin
Why Is Teresa Lambe Influential?
(Suggest an Edit or Addition)According to Wikipedia, Teresa "Tess" Lambe OBE is an Irish scientist working at Oxford University's Oxford Vaccine Group. She is one of the co-developers of the Oxford–AstraZeneca COVID-19 vaccine against the new coronavirus causing COVID-19.
Teresa Lambe's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK (2020) (3297)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (2020) (1480)
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial (2020) (1079)
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021) (937)
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) (850)
- A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity (2005) (839)
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials (2021) (812)
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (733)
- Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection (2021) (730)
- Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (2021) (576)
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2022) (529)
- DNA repair is limiting for haematopoietic stem cells during ageing (2007) (520)
- Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) (427)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (404)
- Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1 (2011) (385)
- Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera (2021) (373)
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2020) (367)
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022) (306)
- Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial (2021) (297)
- A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. (2015) (295)
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial (2021) (275)
- Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production (2009) (263)
- ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (261)
- Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum (2021) (247)
- Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans (2012) (247)
- Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors (2020) (237)
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2020) (228)
- Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? (2008) (200)
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study (2022) (183)
- DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice (2011) (178)
- Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens (2013) (167)
- Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens (2012) (162)
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) (2021) (150)
- Viral vectors as vaccine platforms: from immunogenicity to impact. (2016) (141)
- Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial (2020) (138)
- ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice (2017) (136)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models (2021) (124)
- A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years (2012) (123)
- DOCK8 is essential for T‐cell survival and the maintenance of CD8+ T‐cell memory (2011) (121)
- Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial (2021) (108)
- Immune privilege or privileged immunity? (2008) (108)
- Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults (2018) (105)
- Themis is a member of a new metazoan gene family and is required for completion of thymocyte positive selection (2009) (104)
- High Glucose-altered Gene Expression in Mesangial Cells (2002) (97)
- Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa (2021) (96)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial (2021) (93)
- T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses (2020) (88)
- Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice (2021) (85)
- A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques (2020) (82)
- Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. (2009) (81)
- Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2021) (80)
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model (2017) (80)
- Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 (2020) (77)
- DOCK8 is critical for the survival and function of NKT cells. (2013) (76)
- Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1 (2013) (73)
- The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world (2020) (73)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (2021) (72)
- Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels (2019) (68)
- Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19 (2020) (66)
- MyD88‐dependent autoimmune disease in Lyn‐deficient mice (2007) (66)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial (2021) (65)
- What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins (2016) (65)
- Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine (2021) (61)
- CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions1 (2006) (61)
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogens (2017) (59)
- MAIT cell activation augments adenovirus vector vaccine immunogenicity (2020) (58)
- CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells (2020) (57)
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial (2022) (55)
- A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice (2020) (53)
- Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine (2021) (53)
- CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis (2006) (53)
- Limited Peripheral T Cell Anergy Predisposes to Retinal Autoimmunity1 (2007) (50)
- Potent cross-reactive antibodies following Omicron breakthrough in vaccinees (2022) (46)
- Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques (2021) (45)
- AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein–specific TH1 response with a diverse TCR repertoire (2021) (42)
- Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA‐NP+M1 coadministration with inactivated influenza vaccine (2013) (40)
- Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (39)
- Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum (2022) (39)
- Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge (2019) (39)
- Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. (2022) (38)
- Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation (2004) (37)
- Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 (2021) (36)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil (2021) (35)
- Vaccine platforms for the prevention of Lassa fever (2019) (33)
- Clinical Advances in Viral-Vectored Influenza Vaccines (2018) (33)
- A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? (2017) (33)
- ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 (2021) (33)
- A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters (2019) (33)
- Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges (2015) (31)
- Polyethyleneimine is a potent mucosal adjuvant for glycoproteins with innate and adaptive immune activating properties (2012) (31)
- B-cell tolerance. (2006) (29)
- Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya (2021) (29)
- (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397(10269), 99-111. (2020) (29)
- Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice (2019) (28)
- Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. (2006) (28)
- The Essential Role of DOCK8 in Humoral Immunity (2010) (28)
- Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses (2021) (27)
- Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222) (2021) (26)
- ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets (2021) (26)
- A naturally protective epitope of limited variability as an influenza vaccine target (2018) (25)
- ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 (2021) (25)
- Novel Viral Vectored Vaccines for the Prevention of Influenza (2012) (25)
- Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial (2022) (24)
- Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA (2012) (24)
- Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients (2021) (22)
- T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent–inactivated Influenza Vaccine (2012) (22)
- The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies (2021) (21)
- Safety and Immunogenicity Report from the Com-COV Study – a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine (2021) (21)
- Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells (2020) (21)
- ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2020) (20)
- Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques (2021) (19)
- Manufacturing a chimpanzee adenovirus‐vectored SARS‐CoV‐2 vaccine to meet global needs (2021) (19)
- Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV (2022) (19)
- HLA‐E: exploiting pathogen‐host interactions for vaccine development (2019) (18)
- ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge (2021) (18)
- The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver (2017) (18)
- Divergent trajectories of antiviral memory after SARS-CoV-2 infection (2021) (18)
- Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge (2017) (17)
- Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines. (2016) (17)
- T-cell mediated immunity after AZD1222 vaccination: A polyfunctional spike-specific Th1 response with a diverse TCR repertoire (2021) (16)
- Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial (2022) (15)
- A single dose of ChAdOx1 MERS provides broad protective immunity against a variety of MERS-CoV strains (2020) (15)
- Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2021) (15)
- Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. (2016) (14)
- DOCK 8 deficiency impairs CD 8 T cell survival and function in humans and mice (2011) (14)
- Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya (2021) (13)
- ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models (2021) (13)
- Corrigendum: Themis is a member of a new metazoan gene family and is required for the completion of thymocyte positive selection (2010) (13)
- Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial (2022) (12)
- Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity (2021) (12)
- Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model (2022) (12)
- Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection (2022) (11)
- Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection (2021) (10)
- Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid (2016) (10)
- Differential expression of connexin 43 in mouse mammary cells (2006) (10)
- Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (2021) (10)
- A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector (2020) (9)
- ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants (2022) (8)
- Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b–2a trial (2022) (7)
- ChAdOx1 nCoV-19 (AZD1222) Vaccine in People Living With and Without HIV (2021) (7)
- COVID Symptoms, Seroprevalence, and Mortality During the First Wave of SARS-CoV-2 in Canada (2021) (6)
- MVA-NP+M1 vaccine activates mucosal M1-specific T cell immunity and tissue-resident memory T cells in human nasopharynx-associated lymphoid tissue. (2019) (6)
- Viral vector vaccines (2022) (6)
- A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75 (2022) (6)
- Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility (2022) (6)
- What Constitutes Protective Immunity Following Yellow Fever Vaccination? (2021) (6)
- Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus (2022) (5)
- A single-dose ChAdOx 1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters (2019) (5)
- The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever (2021) (5)
- Modified Vaccinia Ankara–Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue (2019) (5)
- Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (2018) (5)
- ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models (2021) (5)
- Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques (2020) (5)
- Emergency Ebola response. a new approach to the rapid design and development of vaccines against emerging diseases (vol 15, pg 356, 2015) (2015) (4)
- Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses (2021) (4)
- DOCK 8 de ! ciency impairs CD 8 T cell survival and function in humans and mice (2011) (4)
- Recombinant protein vaccines against SARS-CoV-2 (2021) (4)
- CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination (2022) (4)
- Corrigendum: Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production (2010) (3)
- Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (S2352396418300653) (10.1016/j.ebiom.2018.02.011)) (2018) (3)
- Randomized Immunogenicity and Safety Study of Heterologous Versus Homologous COVID-19 Booster Vaccination in Previous Recipients of Two Doses Of Coronavac COVID-19 Vaccine (2021) (3)
- Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs (2021) (3)
- An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females (2022) (3)
- The essential role of DOCK 8 in humoral immunity (2014) (3)
- Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination (2022) (2)
- Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters (2022) (2)
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial (2021) (2)
- Prevalence of SARS-CoV-2 Antibodies from a one-year National Serosurveillance of Kenyan Blood Transfusion Donors (2021) (2)
- Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility (2021) (2)
- Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (2021) (2)
- Harmonization and qualification of an IFN-γ Enzyme-Linked ImmunoSpot assay (ELISPOT) to measure influenza-specific cell-mediated immunity within the FLUCOP consortium (2022) (2)
- Risk factors for Crimean-Congo Haemorrhagic Fever (CCHF) virus exposure in farming communities in Uganda (2022) (2)
- ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys (2021) (1)
- Immunization with matrix-, nucleoprotein and neuraminidase protects against H3N2 influenza challenge in pH1N1 pre-exposed pigs (2023) (1)
- Identification of an epitope of limited variability under strong immune selection in the haemagglutinin head domain of H1N1 influenza (2017) (1)
- Development of low bio-containment assays to characterise the antibody responses in pigs to Nipah virus vaccine candidates (2019) (1)
- Erratum: High glucose-altered gene expression in mesangial cells. Actin-regulatory protein gene expression is triggered by oxidative stress and cytoskeletal disassembly (The Journal of Biological Chemistry (2002) 277 (9707-9712)) (2002) (1)
- Efficacy of the AZD1222 (ChAdOx1 nCoV-19) COVID-19 Vaccine Against SARS-CoV-2 Variants of Concern (2022) (1)
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro (2022) (1)
- An epitope of limited variability as a novel influenza vaccine target (2017) (1)
- CD4+ and CD8+ T cell and antibody correlates of protection against Delta vaccine breakthrough infection: A nested case-control study within the PITCH study (2023) (1)
- Corrections. Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. (2015) (1)
- Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6 (2022) (1)
- Why do breakthrough COVID-19 infections occur in the vaccinated? (2021) (1)
- Safety and Immunogenicity of the ChadOx1 nCoV-19 (AZD1222) Vaccine in Children Aged 12-17 Years: A Preliminary Report of a Phase 2, Single-Blind, Randomised Controlled Trial (COV006) (2021) (1)
- A potent neutralizing epitope of limited variability in the head domain of haemagglutinin as a novel influenza vaccine target (2018) (1)
- Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR (2022) (1)
- T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa (2022) (1)
- Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial (2023) (0)
- Evaluating the potential of novel virus-vectored vaccines as intranasal vaccine candidates for broad immunity against influenza (2015) (0)
- A naturally protective epitope of limited variability as an influenza vaccine target (2018) (0)
- Immunogenicity and Reactogenicity of BNT162b2 and mRNA1273 COVID-19 Vaccines Given as Fourth Dose Boosters in the COV-BOOST Randomised Trial Following Two Doses of ChAdOx1 nCov-19 or BNT162b2 and a Third Dose of BNT162b2 (2022) (0)
- Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens (2023) (0)
- Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials (2023) (0)
- Repertoire sharing between CD4(+) T follicular helper cells in peripheral blood and tonsil (2019) (0)
- Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction (2021) (0)
- Safety and Immunogenicity of a candidate MERS-CoV Viral Vectored Vaccine: a phase I, open- labelled, first-in-human, dose-escalation trial (2020) (0)
- CD4+ T follicular helper (Tfh) cells in human tonsil and blood are clonally convergent, but divergent from non-Tfh CD4+ cells (2019) (0)
- Why acute inflammatory response can happen after Adenoviral Vector Vaccines; Is the interleukin 6 the secret and how circumvent that, Is by adding polyethylene glycol (PEG)? (2021) (0)
- Development of anti-Crimean-Congo hemorrhagic fever virus Gc and NP-specific ELISA for detection of antibodies in domestic animal sera (2022) (0)
- A of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines? (2017) (0)
- Omicron BA.1/BA.2 infections in triple-vaccinated individuals enhance a diverse repertoire of mucosal and blood immune responses (2023) (0)
- CLINICAL DEVELOPMENT OF VIRAL VECTORED VACCINES AGAINST MERS-COV (2018) (0)
- Combined Oligonucleotide and Protein Microarray Temporal Analysis of p53-mediated Apoptosis (2005) (0)
- Protection from liver-stage malaria is dependent on a fine balance between the number of infected hepatocytes and effector CD8+ T cells (2014) (0)
- Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial (2023) (0)
- The AZD1222 COVID-19 vaccine induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire in humans (0)
- Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster (2023) (0)
- Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study – A single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines (2023) (0)
- Publisher Correction: ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques (2021) (0)
- The role of the novel guanine exchange factor, dedicator of cytokinesis 8 (DOCK8), in T cell survival and maintenance of CD8(+) T cell memory (2012) (0)
- Erratum: Themis is a member of a new metazoan gene family and is required for the completion of thymocyte positive selection (Nature Immunology (2009) 10 (831-839)) (2010) (0)
- Novel MVA-based vaccine expressing influenza NP and M1 activates cross-reactive T cell responses in human nasopharynx-associated lymphoid tissue (NALT) (2018) (0)
- A Mouse Model Of Spontaneous Autoimmune Uveoretinis (2006) (0)
- Structural epitope profiling identifies antibodies associated with critical COVID-19 and long COVID (2022) (0)
- Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511] (2023) (0)
- Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model (2017) (0)
- Replication Data for: Temporal trends of SARS-CoV-2 seroprevalence in transfusion blood donors during the first wave of the COVID-19 epidemic in Kenya (2021) (0)
- Immunodeficiency and Abnormal B Cell Synapse Formation due to DOCK8 Mutations in Mice (2010) (0)
- ChAdOx1 nCoV-19 vaccination generates spike-specific CD8+ T cells in aged mice. (2023) (0)
- Protection from liver-stage malaria is dependent on a fine balance between the number of infected hepatocytes and effector CD8+ T cells (2014) (0)
- Vaccination and immunotherapy of viral diseases (PP-069) (2010) (0)
- Efficacy of Primary Series AZD1222 (ChAdOx1 nCoV-19) Vaccination Against SARS-CoV-2 Variants of Concern: Final Analysis of a Randomized, Placebo-controlled, Phase 1b/2 Study in South African Adults (COV005) (2023) (0)
- ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge (2021) (0)
- Response to Letter to the Editor by Ish et al. entitled ‘COVID-19 vaccine equity—the need of the hour’ (2022) (0)
- Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination (2023) (0)
- Commmentary 7 (2008) (0)
- Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model (2023) (0)
- of a Novel Heterosubtypic Influenza A Vaccine, MVA2NP1M1 (2011) (0)
- Durability of ChAdOx1 nCoV-19 (AZD1222) Vaccine and Hybrid Humoral Immunity Against Variants Including Omicron BA.1 and BA.4 Six Months after Vaccination: A Randomised, Phase 1b/2a Trial (2022) (0)
- MERS-CoV Spike Glycoprotein (GP) – ELISA Jenner Clinical SOP Template v1 (2020) (0)
- Long-term respiratory mucosal immune memory to SARS-CoV-2 after infection and vaccination (2023) (0)
- Replication Data for: Prevalence of SARS-CoV-2 Antibodies from a one-year National Serosurveillance of Kenyan Blood Transfusion Donors (2021) (0)
This paper list is powered by the following services:
Other Resources About Teresa Lambe
What Schools Are Affiliated With Teresa Lambe?
Teresa Lambe is affiliated with the following schools:
